Gwenn Hansen Sells 3,377 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,377 shares of the company’s stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the transaction, the insider now owns 61,516 shares in the company, valued at approximately $707,434. The trade was a 5.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Gwenn Hansen also recently made the following trade(s):

• On Thursday, January 30th, Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock. The shares were sold at an average price of $19.85, for a total value of $73,246.50.

Nurix Therapeutics Trading Down 3.2 %

Shares of NRIX opened at $11.16 on Friday. The stock has a 50-day moving average price of $12.13 and a 200-day moving average price of $18.08. The company has a market cap of $850.79 million, a PE ratio of -3.86 and a beta of 2.23. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.05. The business had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period in the previous year, the business posted ($0.76) earnings per share. As a group, analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its position in Nurix Therapeutics by 85.2% during the third quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company’s stock valued at $1,531,000 after purchasing an additional 31,352 shares in the last quarter. Jump Financial LLC purchased a new position in shares of Nurix Therapeutics during the 4th quarter valued at about $1,406,000. Barclays PLC lifted its position in Nurix Therapeutics by 77.9% in the 3rd quarter. Barclays PLC now owns 128,344 shares of the company’s stock worth $2,884,000 after buying an additional 56,190 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in Nurix Therapeutics by 42.7% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company’s stock worth $14,869,000 after buying an additional 235,971 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its position in Nurix Therapeutics by 9.3% during the fourth quarter. Affinity Asset Advisors LLC now owns 940,083 shares of the company’s stock valued at $17,711,000 after acquiring an additional 79,684 shares during the last quarter.

Wall Street Analysts Forecast Growth

NRIX has been the topic of a number of research reports. JPMorgan Chase & Co. lowered their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Leerink Partnrs upgraded shares of Nurix Therapeutics to a “hold” rating in a research note on Monday, March 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Nurix Therapeutics in a report on Tuesday. Leerink Partners started coverage on shares of Nurix Therapeutics in a report on Monday, March 17th. They set a “market perform” rating and a $16.00 target price on the stock. Finally, Stifel Nicolaus cut their price target on Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, April 9th. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $30.44.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.